AgeX Therapeutics, CEO and Founder
Michael West’s entire career has been focused on unraveling the mysteries of human aging, from his scientific training, to his founding and running a variety of successful biotechnology companies, to authoring a popular book on the topic.
Dr. West founded AgeX Therapeutics (NYSE US: AGE) in 2017 with backing from biotech investor Jim Mellon and others. Prior to that, he served as CEO/co-CEO of BioTime, a leader in embryonic stem cell-based therapy, for ten years. From 1998 to 2007, he served in a variety of positions including Chairman, Chief Scientific Officer and CEO at Advanced Cell Technology (ACT), which initiated the world's first human embryonic stem cell-based clinical trial (for age-related macular degeneration). ACT was re-branded Ocata Therapeutics and acquired by Japanese pharma giant Astellas in 2016 for $379 million.
With backing from Kleiner Perkins, Venrock and others, Dr. West founded Geron (short for Gerontology), probably the first regenerative medicine company, in 1990. While at Geron he created the research consortium with Prof. James Thomson that led to the first isolation of human embryonic stem cells, and recruited for the company's scientific team Drs. Elizabeth Blackburn, Jack Szostak and Carol Greider, who went on to win the 2009 Nobel Prize in Medicine.
Dr. West holds a B.S. from Rensselaer Polytechnic Institute, an M.S. in Biology from Andrews University, and a PhD from Baylor College of Medicine, focused on the biology of cellular aging. He is the author of numerous articles in peer-reviewed scientific journals, as well as The Immortal Cell: One Scientist’s Quest to Solve the Mystery of Human Aging (Doubleday, 2003).
Dr. West has been interviewed on NBC's "Meet the Press" and has testified before Congress about the life-extending potential of regenerative medicine.
Novel therapeutics targeting human aging.